Jiankuan Shi1, Yuanlin Zhao2, Yuan Yuan2, Chao Wang2, Zhonglin Xie3, Xing Gao2, Liming Xiao2, Jing Ye4. 1. Department of Pathology, School of Basic Medicine, Fourth Military Medical University, Xi'an 710032; Department of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China. 2. Department of Pathology, School of Basic Medicine, Fourth Military Medical University, Xi'an 710032, China. 3. Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. 4. Department of Pathology, School of Basic Medicine, Fourth Military Medical University, Xi'an 710032, China. *Corresponding author, E-mail: yejing@fmmu.edu.cn.
Abstract
OBJECTIVE: To explore the correlations of the expression of mutant isocitrate dehydrogenase (IDH1) (R132H) protein with angiogenesis and cell proliferation in glioma. METHODS: We performed polymerase chain reaction-based IDH gene mutation screening in 385 glioma samples, and the subcellular localization and expression levels of IDH1 (R132H) was examined by immunohistochemistry (IHC). Ki-67 labeling index was introduced to determine the proliferation of glioma cells, and the microvessel density was measured through CD34 staining. Statistical analyses were performed to show the correlations of IDH1 mutation with cell proliferation and microvessel density. RESULTS: The mutant rates of IDH1 were about 50%-60% in grade II-III gliomas and secondary glioblastomas, which were significantly higher than those in pilocytic astrocytoma (grade I) and primary glioblastoma (grade IV). Moreover, the level of IDH1 (R132H) protein was positively correlated with Ki-67 labeling index and microvessel density. CONCLUSION: IDH mutation was common in grade II-III glioma and secondary glioblastoma, and the mutant IDH1 (R132H) might play a critical role in the cell proliferation and angiogenesis of glioma.
OBJECTIVE: To explore the correlations of the expression of mutant isocitrate dehydrogenase (IDH1) (R132H) protein with angiogenesis and cell proliferation in glioma. METHODS: We performed polymerase chain reaction-based IDH gene mutation screening in 385 glioma samples, and the subcellular localization and expression levels of IDH1 (R132H) was examined by immunohistochemistry (IHC). Ki-67 labeling index was introduced to determine the proliferation of glioma cells, and the microvessel density was measured through CD34 staining. Statistical analyses were performed to show the correlations of IDH1 mutation with cell proliferation and microvessel density. RESULTS: The mutant rates of IDH1 were about 50%-60% in grade II-III gliomas and secondary glioblastomas, which were significantly higher than those in pilocytic astrocytoma (grade I) and primary glioblastoma (grade IV). Moreover, the level of IDH1 (R132H) protein was positively correlated with Ki-67 labeling index and microvessel density. CONCLUSION:IDH mutation was common in grade II-III glioma and secondary glioblastoma, and the mutant IDH1 (R132H) might play a critical role in the cell proliferation and angiogenesis of glioma.
Authors: Kamel El Salek; Islam S Hassan; Aikaterini Kotrotsou; Srishti Abrol; Scott H Faro; Feroze B Mohamed; Pascal O Zinn; Wei Wei; Nan Li; Ashok J Kumar; Jeffrey S Weinberg; Jeffrey S Wefel; Shelli R Kesler; Ho-Ling Anthony Liu; Ping Hou; R Jason Stafford; Sujit Prabhu; Raymond Sawaya; Rivka R Colen Journal: Sci Rep Date: 2017-09-21 Impact factor: 4.379